ALLK News and Press, Allakos Inc. From 07/08/21

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Allakos ([[ALLK]] +3.0%) has completed enrollment in its Phase 3 study of lirentelimab in patients with eosinophilic gastritis ((EG)) and/or eosinophilic duodenitis ((EoD)), and its Phase 2/3 study of lirentelimab in patients with eosinophilic esophagitis ((EoE)).Clinical trial results f...

-- Results from both clinical trials expected in the fourth quarter of 2021 -- -- CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson, SVP of Clinical Development and Medical Affairs, promoted to CMO -- REDWOOD CITY, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Allakos Inc...

REDWOOD CITY, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, reported data at Digestive Disease Week (DDW) 2021. ...

Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonable prices for biotech companies, according to Jefferies analyst Michael Yee."Typically, we see 3-5 [month] corrections…[and] then pharma starts to step in and finalize deals,...

Allakos (ALLK): Q1 GAAP EPS of -$1.04 misses by $0.19.Cash, cash equivalents and marketable securities of $615.9M.Press Release For further details see: Allakos EPS misses by $0.19

REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter en...

Allakos (ALLK) appointed Baird Radford as CFO; he has 25 years of finance and leadership experience at public companies in multiple industries and various stages of growth.Most recently, he served as SVP, Finance at Aimmune Therapeutics."With lirentelimab in a Phase 3 pivotal study, this is a...

REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird R...

REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptan...